Resistanc

Antibiotics Don't Prevent Future Urinary Tract Infections, May Cause Resistance in Future Infections

PHILADELPHIA, July 10, 2007 /PRNewswire-USNewswire/ -- After afirst childhood urinary tract infection (UTI), daily antibioticsmay not prevent another such infection, and may actually increasethe risk that the next urinary tract infection is caused byresistant bacteria, according to a new study in the July 11 issueof the Journal of the American Medical Association. In the first larg...

TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials

Data Published in The Lancet on TMC125, an Investigational NNRTIfrom Tibotec YARDLEY, Pa., July 05, 2007 /PRNewswire/ -- Data from twoongoing Phase 3 studies (DUET-1 and DUET-2) showed significantlymore HIV-1 adult patients with documented non-nucleoside reversetranscriptase inhibitor (NNRTI) and protease inhibitor (PI)resistance reached an undetectable viral load (defined as achievingco...

Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers

WASHINGTON, January 29, 2007 /PRNewswire-USNewswire/ -- RearAdmiral Timothy Ziemer (U.S. Navy, retired), the President'sMalaria Coordinator, announced his intent to name Dr. BernardNahlen to serve as Deputy Coordinator of the President's MalariaInitiative (PMI). Dr. Nahlen is a Commissioned Officer in the U.S.Public Heath Service and has most recently served as SeniorAdvisor, Monitoring...

Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23

SAN DIEGO, June 21, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM)Therapeutics, Inc. , a biopharmaceutical company focused on thetreatment of central nervous system disorders with an initial focuson obesity, today announced that the Company will present dataabout its lead obesity product candidate Contrave(TM) and itseffect on markers of cardiovascular disease (visceral fat, serumcholestero...

Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop

PRINCETON, N.J., June 14, 2007 /PRNewswire-FirstCall/ --Pharmasset, Inc. , a clinical-stage pharmaceutical companycommitted to discovering, developing and commercializing noveldrugs to treat viral infections, announced today that scientificdata presentations about Clevudine and Racivir were made during the16th International HIV Drug Resistance Workshop being held in St.Michael, Barbados...

Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos' Bevirimat

WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2007 - PanacosPharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology companydedicated to developing the next generation of antiviraltherapeutic products, today announced the results of a new studyindicating that HIV resistant to Protease Inhibitors (PI) may havereduced potential for the development of resistance to the HIVmaturation inhibitor bevirim...

GTx Announces Ostarine Improved Insulin Resistance among Elderly Patients in a Recently Completed Phase II Clinical Trial

MEMPHIS, Tenn.--(BUSINESS WIRE)--Apr 17, 2007 - GTx, Inc. (NASDAQ:GTXI) announced today that data from a recently conducted Phase IIOstarine(TM) clinical trial of 60 elderly men and 60 postmenopausalwomen revealed that insulin and glucose levels were reduced andinsulin resistance was improved among subjects receiving the 3 mgdose of Ostarine compared to baseline. These observations were even...